3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Leukemia, Myeloid, Acute
3
Neoplasm, Residual
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Plasma Cell
1
Chromosome 17 deletion
1
Interventions
Cyclophosphamide
149
Rituximab
104
Peripheral Blood Stem Cell Transplantation
101
fludarabine phosphate
100
Filgrastim
72
Mycophenolic Acid
67
Cyclosporine
59
Radiotherapy
58
Whole-Body Irradiation
57
Etoposide
55
Tacrolimus
51
Busulfan
50
Antilymphocyte Serum
43
Melphalan
41
Methotrexate
37
Cytarabine
27
Cord Blood Stem Cell Transplantation
26
fludarabine
25
Bortezomib
24
Methylprednisolone
23
Carmustine
22
sargramostim
21
Flow Cytometry
19
Dexamethasone
19
Lenalidomide
18
Granulocyte Colony-Stimulating Factor
18
Vincristine
17
Prednisone
17
Bendamustine Hydrochloride
17
aldesleukin
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
Maintenance
×
Other hematologic neoplasm
×
Clear all
NCT04542824
2026-06-02
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled